BofA Cuts West Pharmaceutical (WST) Target Following Model Update and Sector Pressure

robot
Abstract generation in progress

BofA lowered its price target for West Pharmaceutical Services (WST) from $370 to $300, while reiterating a Buy rating, following a model update and broader sector pressure. The adjustment came after the company released strong year-end results and better-than-expected FY26 guidance, driven by growth in its non-GLP-1 high-value products. West Pharmaceutical also declared a quarterly dividend of $0.22 per share and authorized a new $1 billion share repurchase program, reinforcing its commitment to shareholder returns.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)